Equities

CERo Therapeutics Holdings Inc

CERO:NMQ

CERo Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.119
  • Today's Change0.032 / 36.78%
  • Shares traded156.74m
  • 1 Year change-98.91%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.100.481.10
Total Receivables, Net------
Total Inventory------
Prepaid expenses0.030.230.26
Other current assets, total8.4442--
Total current assets8.56421.36
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments--0178
Note receivable - long term------
Other long term assets------
Total assets8.5642180
LIABILITIES
Accounts payable------
Accrued expenses0.0600.08
Notes payable/short-term debt1.560.650
Current portion long-term debt/capital leases------
Other current liabilities, total0.03280.00
Total current liabilities5.17310.10
Total long term debt000
Total debt1.560.650
Deferred income tax------
Minority interest------
Other liabilities, total9.159.159.15
Total liabilities14409.25
SHAREHOLDERS EQUITY
Common stock8.4413179
Additional paid-in capital--00
Retained earnings (accumulated deficit)(14)(11)(7.67)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(5.76)2.47171
Total liabilities & shareholders' equity8.5642180
Total common shares outstanding6.256.7723
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.